Ru Feng

机构：Xuzhou Medical College, Third Affiliated Hospital of Southern Medical University, Nanfang Hospital, Second People’s Hospital of Huai’an, Southern Medical University · ORCID：0000-0003-4585-554X

发表论文 52 篇 · 总被引 230 次 · h-index 7

代表论文

• BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2024 · Blood · 被引 20)
• Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study (2025 · 癌症：英文版 · 被引 14)
• CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis (2025 · iScience · 被引 7)
• Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (2025 · Journal of Clinical Oncology · 被引 1)
• Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (2025 · Journal of Clinical Oncology · 被引 1)
• 591 | NOVEL CHEMOTHERAPY‐FREE INITIAL TREATMENT OF RITUXIMAB PLUS PEGYLATED INTERFERON Α‐2B IN UNTREATED ADVANCED INDOLENT B‐CELL LYMPHOMA: 4‐YEAR FOLLOW‐UP STUDY (2025 · Hematological Oncology · 被引 1)